<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9733">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00724594</url>
  </required_header>
  <id_info>
    <org_study_id>R01NS052448</org_study_id>
    <secondary_id>R01NS052448</secondary_id>
    <nct_id>NCT00724594</nct_id>
  </id_info>
  <brief_title>Safety of N-acetylcysteine in Maternal Chorioamnionitis (NAC in Chorio)</brief_title>
  <official_title>Safety of N-acetylcysteine in Maternal Chorioamnionitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of South Carolina</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Neurological Disorders and Stroke (NINDS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Medical University of South Carolina</source>
  <oversight_info>
    <authority>United States: Federal Government</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this trial was to find the best dose of N-acetylcysteine (NAC) to decrease
      brain injury in babies exposed to intrauterine infection without causing significant side
      effects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Chorioamnionitits is an infection in the fluid and membranes surrounding the baby in utero.
      Intrauterine infection is associated with significant white and grey matter brain injury in
      newborns and is particularly important in the pathogenesis of periventricular leukomalacia
      (PVL) and cerebral palsy (CP). CP has been shown to be 4-9 times higher in babies exposed to
      intrauterine infection than in normal infants. Antibiotics have not changed the risk for
      brain injury in the newborn.

      NAC is a promising anti-oxidant therapy that has shown effective neuroprotection in an
      animal model of chorioamnionitis, and has a favorable safety profile with limited and
      manageable side effects.

      In this trial, intravenous NAC was given to mothers antenatally and to their infants
      postnatally, who presented with the diagnosis of chorioamnionitis, to evaluate safety and
      pharmacokinetics (PK) in mothers and infants. Mothers at ≥24 weeks gestation and their
      infants were randomized to receive either saline NAC within 4 hours of a clinical diagnosis
      of chorioamnionitis. Infants were stratified into term (≥ 33wk) and preterm (24-32wk)
      cohorts, due to different expected rates of metabolism and clearance.

      Information gained from this trial will be used to determine how rapidly NAC is metabolized
      by mother, fetus, infant, and the ability of NAC to cross placenta. This study will also
      elucidate the safety of NAC in the setting of chorioamnionitis for fetal neuroprotection.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2008</start_date>
  <completion_date type="Actual">August 2014</completion_date>
  <primary_completion_date type="Actual">July 2014</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>NAC Terminal Elimination Half-life</measure>
    <time_frame>prior to delivery in mothers, and in newborn after delivery during 2 days of NAC infusion</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>NAC Volume of Distribution</measure>
    <time_frame>prior to delivery in mothers, and in newborn after delivery during 2 days of NAC infusion</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>NAC Total Body Clearance</measure>
    <time_frame>prior to delivery in mothers, and in newborn after delivery during 2 days of NAC infusion</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>NAC Concentrations</measure>
    <time_frame>Peak: 30 minutes after NAC infusion. Cord: at delivery</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Placental Transfer Ratio</measure>
    <time_frame>At time of delivery</time_frame>
    <safety_issue>No</safety_issue>
    <description>Ratio of NAC concentration in cord to maternal venous blood</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maternal and Infant Mean Blood Pressure Change</measure>
    <time_frame>Maternal mean BP changes were pre/post dosing prior to delivery. Infant measurements were pre/post their first dosing</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Cerebral Blood Flow</measure>
    <time_frame>prior to delivery and in newborn after delivery, during 2 days of NAC infusion</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>PT</measure>
    <time_frame>prior to delivery and in newborn DOL1</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Magnetic Resonance Spectroscopy of Infants</measure>
    <time_frame>36 - 40 weeks gestational age</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cytokine Levels in Plasma and CSF</measure>
    <time_frame>During 2 days of NAC infusion</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">46</enrollment>
  <condition>Chorioamnionitis</condition>
  <condition>Brain Injury</condition>
  <arm_group>
    <arm_group_label>N-acetylcysteine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mother/infant pairs were stratified by gestational age into premature (P) and term (T) cohorts.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Mother/infant pairs were stratified by gestational age into premature (P) and term (T) cohorts.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>N-acetylcysteine</intervention_name>
    <description>NAC (100 mg/kg/dose) was given intravenously to mothers within 4 hours of diagnosis of chorioamnionitis, and every 6 hours until delivery. NAC was given to preterm (12.5 mg/kg/dose) and term infants (25 mg/kg/dose) every 12 hours for 5 doses after birth.</description>
    <arm_group_label>N-acetylcysteine</arm_group_label>
    <other_name>Acetadote, NAC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Control</intervention_name>
    <description>Saline was given in the same volume, at the same timing as NAC infusions</description>
    <arm_group_label>Control</arm_group_label>
    <other_name>Saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Participants had all of the following to qualify:

          -  Chorioamnionitis, defined as either 1) clinical diagnosis of choriomanionitis 2)
             maternal fever greater than or equal to 100 degrees F in the presence of rupture of
             membranes or 2 of the following: uterine tenderness, maternal WBC &gt; 15,000 cells/mm,
             fetal tachycardia &gt; 160 bpm, malodorous amniotic fluid, or in preterm group only,
             rupture of membranes and active preterm labor.

          -  Gestational age ≥ 24 completed weeks, by first trimester ultrasound or date of last
             menstrual period.

          -  No greater than 4 hours from onset of fever or diagnosis.

        Exclusion Criteria:

        Participants had none of the following:

          -  Asthma, steroid-dependent

          -  Clinical sepsis, whether viral or bacterial in nature, defined as fever with signs of
             cardiovascular compromise in mother (blood pressure &lt; 90/50, heart rate &gt; 120 bpm,
             need for oxygen due to maternal saturations below 92%, pneumonia, pyelonephritis, or
             meningitis)

          -  Seizure disorder

          -  Fetal weight or biparietal diameter less than the 10th% for gestational age

          -  Suspected major genetic or congenital abnormality

          -  Fetal distress which demands immediate delivery (poor fetal biophysical profile, late
             decelerations, sinusoidal fetal heart rate pattern)

          -  Participation in another therapeutic clinical trial
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dorothea D. Jenkins, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of South Carolina</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eugene Chang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of South Carolina (Obstetric Principal Investigator)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Wiest DB, Chang E, Fanning D, Garner S, Cox T, Jenkins DD. Antenatal pharmacokinetics and placental transfer of N-acetylcysteine in chorioamnionitis for fetal neuroprotection. J Pediatr. 2014 Oct;165(4):672-7.e2. doi: 10.1016/j.jpeds.2014.06.044. Epub 2014 Jul 23.</citation>
    <PMID>25064164</PMID>
  </results_reference>
  <verification_date>May 2015</verification_date>
  <lastchanged_date>May 8, 2015</lastchanged_date>
  <firstreceived_date>July 28, 2008</firstreceived_date>
  <firstreceived_results_date>January 9, 2015</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of South Carolina</investigator_affiliation>
    <investigator_full_name>Dorothea D. Jenkins</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>chorioamnionitis</keyword>
  <keyword>maternal chorioamnionitis</keyword>
  <keyword>neonatal white matter injury</keyword>
  <keyword>N-acetylcysteine</keyword>
  <keyword>NAC</keyword>
  <keyword>anti-oxidant treatment</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Chorioamnionitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Acetylcysteine</mesh_term>
    <mesh_term>N-monoacetylcystine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Due two enrolling two sets of twins (one set in the preterm/NAC group, and one set in the preterm/control group), our study included 24 infants and 22 mothers.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>NAC Infant</title>
          <description>Infants treated with N-acetylcysteine</description>
        </group>
        <group group_id="P2">
          <title>Control Infant</title>
          <description>Infants treated with saline</description>
        </group>
        <group group_id="P3">
          <title>NAC Maternal</title>
          <description>Mothers of infants treated with N-acetylcysteine</description>
        </group>
        <group group_id="P4">
          <title>Control Maternal</title>
          <description>Mothers of infants treated with saline</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="11"/>
                <participants group_id="P4" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="11"/>
                <participants group_id="P4" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>NAC Infant</title>
          <description>Infants treated with N-acetylcysteine</description>
        </group>
        <group group_id="B2">
          <title>Control Infant</title>
          <description>Infants treated with saline</description>
        </group>
        <group group_id="B3">
          <title>NAC Maternal</title>
          <description>Mothers of infants treated with N-acetylcysteine</description>
        </group>
        <group group_id="B4">
          <title>Control Maternal</title>
          <description>Mothers of infants treated with saline</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="12"/>
                <measurement group_id="B2" value="12"/>
                <measurement group_id="B3" value="11"/>
                <measurement group_id="B4" value="11"/>
                <measurement group_id="B5" value="46"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Preterm Infants</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="7"/>
                <measurement group_id="B2" value="7"/>
                <measurement group_id="B3" value="NA">Only applicable to infants</measurement>
                <measurement group_id="B4" value="NA">Only applicable to infants</measurement>
                <measurement group_id="B5" value="NA">Total not calculated because data are not available (NA) in one or more arms.</measurement>
              </measurement_list>
            </category>
            <category>
              <sub_title>Term Infants</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="5"/>
                <measurement group_id="B2" value="5"/>
                <measurement group_id="B3" value="NA">Only applicable to infants</measurement>
                <measurement group_id="B4" value="NA">Only applicable to infants</measurement>
                <measurement group_id="B5" value="NA">Total not calculated because data are not available (NA) in one or more arms.</measurement>
              </measurement_list>
            </category>
            <category>
              <sub_title>Mothers aged 18-45years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="NA">Only applicable to mothers</measurement>
                <measurement group_id="B2" value="NA">Only applicable to mothers</measurement>
                <measurement group_id="B3" value="11"/>
                <measurement group_id="B4" value="11"/>
                <measurement group_id="B5" value="NA">Total not calculated because data are not available (NA) in one or more arms.</measurement>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="5"/>
                <measurement group_id="B2" value="6"/>
                <measurement group_id="B3" value="11"/>
                <measurement group_id="B4" value="11"/>
                <measurement group_id="B5" value="33"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="7"/>
                <measurement group_id="B2" value="6"/>
                <measurement group_id="B3" value="0"/>
                <measurement group_id="B4" value="0"/>
                <measurement group_id="B5" value="13"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>American Indian or Alaska Native</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
                <measurement group_id="B4" value="0"/>
                <measurement group_id="B5" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Asian</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
                <measurement group_id="B4" value="0"/>
                <measurement group_id="B5" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Native Hawaiian or Other Pacific Islander</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
                <measurement group_id="B4" value="0"/>
                <measurement group_id="B5" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Black or African American</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="9"/>
                <measurement group_id="B2" value="5"/>
                <measurement group_id="B3" value="8"/>
                <measurement group_id="B4" value="4"/>
                <measurement group_id="B5" value="26"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>White</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="3"/>
                <measurement group_id="B2" value="7"/>
                <measurement group_id="B3" value="3"/>
                <measurement group_id="B4" value="7"/>
                <measurement group_id="B5" value="20"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>More than one race</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
                <measurement group_id="B4" value="0"/>
                <measurement group_id="B5" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Unknown or Not Reported</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
                <measurement group_id="B4" value="0"/>
                <measurement group_id="B5" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="12"/>
                <measurement group_id="B2" value="12"/>
                <measurement group_id="B3" value="11"/>
                <measurement group_id="B4" value="11"/>
                <measurement group_id="B5" value="46"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>NAC Terminal Elimination Half-life</title>
        <time_frame>prior to delivery in mothers, and in newborn after delivery during 2 days of NAC infusion</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>NAC Maternal</title>
            <description>Mothers treated with N-acetylcysteine prior to delivery of infant</description>
          </group>
          <group group_id="O2">
            <title>NAC Preterm Infants</title>
            <description>Preterm infants treated with N-acetylcysteine</description>
          </group>
          <group group_id="O3">
            <title>NAC Term Infants</title>
            <description>Term infants treated with N-acetylcysteine</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="11"/>
                  <measurement group_id="O2" value="7"/>
                  <measurement group_id="O3" value="5"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>NAC Terminal Elimination Half-life</title>
            <units>hours</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="1.2" spread="0.2"/>
                  <measurement group_id="O2" value="7.5" spread="2.0"/>
                  <measurement group_id="O3" value="5.1" spread="1.3"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Magnetic Resonance Spectroscopy of Infants</title>
        <time_frame>36 - 40 weeks gestational age</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>NAC Volume of Distribution</title>
        <time_frame>prior to delivery in mothers, and in newborn after delivery during 2 days of NAC infusion</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>NAC Maternal</title>
            <description>Mothers treated with N-acetylcysteine prior to delivery of infant</description>
          </group>
          <group group_id="O2">
            <title>NAC Preterm Infants</title>
            <description>Preterm infants treated with N-acetylcysteine</description>
          </group>
          <group group_id="O3">
            <title>NAC Term Infants</title>
            <description>Term infants treated with N-acetylcysteine</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="11"/>
                  <measurement group_id="O2" value="7"/>
                  <measurement group_id="O3" value="5"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>NAC Volume of Distribution</title>
            <units>L/kg</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0.41" spread="0.07"/>
                  <measurement group_id="O2" value="0.47" spread="0.04"/>
                  <measurement group_id="O3" value="0.38" spread="0.09"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>NAC Total Body Clearance</title>
        <time_frame>prior to delivery in mothers, and in newborn after delivery during 2 days of NAC infusion</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>NAC Maternal</title>
            <description>Mothers treated with N-acetylcysteine prior to delivery of infant</description>
          </group>
          <group group_id="O2">
            <title>NAC Preterm Infants</title>
            <description>Preterm infants treated with N-acetylcysteine</description>
          </group>
          <group group_id="O3">
            <title>NAC Term Infants</title>
            <description>Term infants treated with N-acetylcysteine</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="11"/>
                  <measurement group_id="O2" value="7"/>
                  <measurement group_id="O3" value="5"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>NAC Total Body Clearance</title>
            <units>mL/h/kg</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="255" spread="61"/>
                  <measurement group_id="O2" value="45.0" spread="8.2"/>
                  <measurement group_id="O3" value="53.7" spread="11.3"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>NAC Concentrations</title>
        <time_frame>Peak: 30 minutes after NAC infusion. Cord: at delivery</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>NAC Maternal</title>
            <description>Mothers treated with N-acetylcysteine prior to delivery</description>
          </group>
          <group group_id="O2">
            <title>NAC Preterm Infants</title>
            <description>Preterm infants treated with N-acetylcysteine</description>
          </group>
          <group group_id="O3">
            <title>NAC Term Infants</title>
            <description>Term infants treated with N-acetylcysteine</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="11"/>
                  <measurement group_id="O2" value="7"/>
                  <measurement group_id="O3" value="5"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>NAC Concentrations</title>
            <units>micromol/L</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Peak NAC concentration in plasma</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1222" spread="415"/>
                  <measurement group_id="O2" value="49.0" spread="14.9"/>
                  <measurement group_id="O3" value="92.3" spread="69.2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>NAC cord concentration</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="NA">Not applicable to mothers</measurement>
                  <measurement group_id="O2" value="370.7" spread="199.2"/>
                  <measurement group_id="O3" value="639.7" spread="409.4"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cytokine Levels in Plasma and CSF</title>
        <time_frame>During 2 days of NAC infusion</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Placental Transfer Ratio</title>
        <description>Ratio of NAC concentration in cord to maternal venous blood</description>
        <time_frame>At time of delivery</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>NAC Maternal</title>
            <description>Mothers treated with N-acetylcysteine prior to birth</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="12"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Placental Transfer Ratio</title>
            <description>Ratio of NAC concentration in cord to maternal venous blood</description>
            <units>ratio</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="1.4" spread="0.8"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maternal and Infant Mean Blood Pressure Change</title>
        <time_frame>Maternal mean BP changes were pre/post dosing prior to delivery. Infant measurements were pre/post their first dosing</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>The infant and maternal populations analyzed for this portion are incomplete, as not all individuals had paired before/after blood pressure measurements at this time point.</population>
        <group_list>
          <group group_id="O1">
            <title>NAC Infants</title>
            <description>Infants treated with N-acetylcysteine</description>
          </group>
          <group group_id="O2">
            <title>Control Infants</title>
            <description>Infants treated with saline</description>
          </group>
          <group group_id="O3">
            <title>NAC Maternal</title>
            <description>Mothers treated with N-acetylcysteine prior to delivery</description>
          </group>
          <group group_id="O4">
            <title>Control Maternal</title>
            <description>Mothers treated with saline prior to delivery</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="10"/>
                  <measurement group_id="O2" value="7"/>
                  <measurement group_id="O3" value="11"/>
                  <measurement group_id="O4" value="10"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Maternal and Infant Mean Blood Pressure Change</title>
            <units>mmHg</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="-1.2" spread="13"/>
                  <measurement group_id="O2" value="2.1" spread="11"/>
                  <measurement group_id="O3" value="1" spread="12"/>
                  <measurement group_id="O4" value="2" spread="10"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cerebral Blood Flow</title>
        <time_frame>prior to delivery and in newborn after delivery, during 2 days of NAC infusion</time_frame>
        <safety_issue>Yes</safety_issue>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>PT</title>
        <time_frame>prior to delivery and in newborn DOL1</time_frame>
        <safety_issue>Yes</safety_issue>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Mothers were monitored for Adverse Events for up to 2 days after treatment. Infants were assessed for Adverse Events until discharge, Serious Adverse Events up to 30 days post-treatment.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>NAC Infant</title>
          <description>Infants treated with N-acetylcysteine</description>
        </group>
        <group group_id="E2">
          <title>Control Infant</title>
          <description>Infants treated with saline</description>
        </group>
        <group group_id="E3">
          <title>NAC Maternal</title>
          <description>Mothers of infants treated with N-acetylcysteine</description>
        </group>
        <group group_id="E4">
          <title>Control Maternal</title>
          <description>Mothers of infants treated with saline</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <description>Resuscitation-chest compressions/CV meds</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Culture Proven Sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>IVH 1-2 days of age</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>IVH 5-7 days of age</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>NEC within 30 days</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Hypoxic Ischemic Encephalopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Prolonged PT time</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="8"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Shortness of breath/wheezing</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash/Hives</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Dorothea Jenkins</name_or_title>
      <organization>Medical University of South Carolina</organization>
      <phone>843-792-4341</phone>
      <email>jenkd@musc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
